| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1997.15.5.2040 |
| P698 | PubMed publication ID | 9164216 |
| P2093 | author name string | F Eschwege | |
| P Rougier | |||
| D G Gonzalez | |||
| M van Glabbeke | |||
| H Bartelink | |||
| D Peiffert | |||
| J F Bosset | |||
| M Pierart | |||
| F Roelofsen | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase III clinical trial | Q42824827 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 2040-2049 | |
| P577 | publication date | 1997-05-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups | |
| P2283 | uses | randomized experiment | Q1231081 |
| P478 | volume | 15 |
| Q33925505 | 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development |
| Q38774791 | A High-Throughput Cell-Based Screen Identified a 2-[(E)-2-Phenylvinyl]-8-Quinolinol Core Structure That Activates p53. |
| Q38767968 | A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature |
| Q88715246 | A Population-Based Cohort Analysis of Chemoradiation Versus Radiation Alone for Definitive Treatment of Stage I Anal Cancer in Older Patients |
| Q35608501 | A cell-based high-throughput screening assay for radiation susceptibility using automated cell counting |
| Q61306914 | A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus |
| Q93271731 | A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer |
| Q37584860 | ACR Appropriateness Criteria®-Anal Cancer |
| Q80510580 | AIDS-associated malignancies |
| Q38746232 | Advances in the Management of Anal Cancer |
| Q42791100 | Anal Cancer debuting as Cancer of Unknown Primary |
| Q33702377 | Anal adenocarcinoma requires prophylactic inguinal nodal treatment: Results from a single Chinese institution |
| Q36648069 | Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy |
| Q35008645 | Anal canal carcinoma treatment results: the experience of a single institution |
| Q37065623 | Anal canal carcinoma: experience from a single Korean institution |
| Q40780999 | Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival |
| Q84337349 | Anal cancer treated with radio-chemotherapy: correlation between length of treatment interruption and outcome |
| Q34465769 | Anal cancer treatment: current status and future perspectives |
| Q35174165 | Anal cancer: an HIV-associated cancer |
| Q38078283 | Anal cancer: are we making progress? |
| Q46318471 | Anal cancer: is neoadjuvant cisplatin chemotherapy or chemoradiotherapy friend or foe? |
| Q30409533 | Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial |
| Q35040439 | Anal neoplasms |
| Q34255528 | Anal squamous cell carcinoma: an evolution in disease and management |
| Q91217701 | Anal squamous cell carcinoma: are we improving outcomes? |
| Q77917851 | Anorectal miscellany: pilonidal disease, anal cancer, Bowen's and Paget's diseases, foreign bodies, and hidradenitis suppurativa |
| Q36620504 | Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy |
| Q50897271 | Background and Current Treatment of Squamous Cell Carcinoma of the Anus. |
| Q37681208 | Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial |
| Q56380424 | Brachytherapy boost after chemoradiation in anal cancer: a systematic review |
| Q88336925 | CHAPTER 5 HPV infection and HPV-associated neoplasia in immunocompromised women |
| Q39551199 | Can radiobiological parameters derived from squamous cell carcinoma of the head and neck be used to predict local control in anal cancer treated with chemoradiation? |
| Q46049378 | Can the radiation dose to CT-enlarged but FDG-PET-negative inguinal lymph nodes in anal cancer be reduced? |
| Q35824265 | Can we omit prophylactic inguinal nodal irradiation in anal cancer patients? |
| Q42702567 | Cancer of the Anal Canal: Diagnosis, Staging and Follow-Up with MRI |
| Q35683341 | Cancer of the anal canal. |
| Q35193297 | Cancers of the anal canal and anal margin |
| Q34710569 | Carcinoma arising within an anal gland |
| Q33888085 | Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature |
| Q44306490 | Chemoradiation for adenocarcinoma of the anus |
| Q52235679 | Chemoradiation for malignant epithelial tumors. |
| Q33783068 | Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). |
| Q34501938 | Chemoradiation schedules--what radiotherapy? |
| Q36564168 | Chemoradiation therapy with S-1 for primary squamous cell carcinoma of the rectum: report of three cases |
| Q90565966 | Chemoradiation versus local excision in treatment of stage I anal squamous cell carcinoma: A population-based analysis |
| Q33729819 | Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma |
| Q36786775 | Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience. |
| Q37643411 | Chemoradiotherapy with Brachytherapy or Electron Therapy Boost for Locally Advanced Squamous Cell Carcinoma of the Anus-Reducing the Colostomy Rate |
| Q58618355 | Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus |
| Q35678065 | Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option |
| Q33314684 | Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients |
| Q98164822 | Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center |
| Q44323781 | Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index |
| Q39276856 | Clinical and Economic Evaluation of Treatment Strategies for T1N0 Anal Canal Cancer |
| Q39214854 | Clinical endpoints in trials of chemoradiation for patients with anal cancer. |
| Q34667668 | Clinical experience of SIB-IMRT in anal cancer and selective literature review. |
| Q37427840 | Clinical trials in the management of anal cancer |
| Q36478774 | Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal |
| Q51035815 | Colorectal squamous cell carcinoma: a rare tumor with poor prognosis. |
| Q74608432 | Combined chemotherapy and radiation for locally advanced cervical carcinoma |
| Q64046189 | Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour |
| Q37768039 | Combined-modality treatment for anal cancer: current strategies and future directions |
| Q58755495 | Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study |
| Q36196016 | Comparison of elective inguinal node irradiation techniques in anal cancer. |
| Q34803620 | Comparison of four 3D conformal treatment techniques to optimise radiotherapy treatment for anal cancer |
| Q63966743 | Complete resolution of anal cancer after chemotherapy for acute myeloid leukaemia |
| Q50018994 | Complex Reconstruction with Flaps After Abdominoperineal Resection and Groin Dissection for Anal Squamous Cell Carcinoma: A Difficult Case Involving Many Specialities. |
| Q40103314 | Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. |
| Q36685452 | Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas |
| Q46310024 | Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma |
| Q77828166 | Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial |
| Q35687600 | Concomitant radiotherapy and chemotherapy for high-risk nonmelanoma skin carcinomas of the head and neck |
| Q26798912 | Concurrent chemoradiation for high-risk prostate cancer |
| Q33593181 | Concurrent chemoradiation with volumetric modulated Arc therapy of patients treated for anal cancer-acute toxicity and treatment outcome |
| Q37340391 | Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost |
| Q33811309 | Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma |
| Q42461171 | Conservative treatment of anorectal tumors |
| Q38975263 | Contemporary Role of Radiotherapy in the Management of Primary Penile Tumors and Metastatic Disease |
| Q47104015 | Contemporary role of radiotherapy in the management of penile cancer |
| Q44466535 | Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study |
| Q74599516 | Conventional cancer therapy: promise broken or promise delayed? |
| Q47158367 | Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer |
| Q37563241 | Correlation between bone marrow dose volumes and acute hematological toxicity in postoperative gynecological cancer patients |
| Q44235298 | Curative radiotherapy in patients with anal cancer: clinical outcomes and prognostic factors in a single-institution experience |
| Q53536535 | Curative-intent radiation therapy in anal carcinoma: quality of life and sphincter function. |
| Q37738173 | Current and emerging treatment strategies for anal cancer |
| Q83590474 | Current management of anal canal cancer |
| Q53363703 | Current therapeutic strategies for anal squamous cell carcinoma in Japan. |
| Q89542928 | Definitive chemoradiotherapy for anal canal cancer: single-center experience |
| Q49417105 | Development and validation of a machine learning-based predictive model to improve the prediction of inguinal status of anal cancer patients: A preliminary report. |
| Q36326671 | Development of cerebral metastasis after medical and surgical treatment of anal squamous cell carcinoma |
| Q37272218 | Diagnosis and management of anal cancer. |
| Q90346342 | Difference in toxicity between HIV-positive and HIV-negative patients with squamous-cell cancer of the anal canal treated with concomitant radio-chemotherapy |
| Q37525301 | Disparities in receipt of radiotherapy and survival by age, sex, and race among patients with non-metastatic squamous cell carcinoma of the anus |
| Q41541911 | Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). |
| Q36621336 | Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer? |
| Q51713174 | Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients. |
| Q33431168 | Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer |
| Q53530286 | EORTC scientific strategy meeting 25-26 March 1999. |
| Q36616658 | Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy |
| Q50034630 | Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy |
| Q78075609 | Effectiveness of surgical salvage therapy for patients with locally uncontrolled anal carcinoma after sphincter-conserving treatment |
| Q60928021 | Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal |
| Q33646367 | Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis |
| Q51004571 | Endoscopic submucosal dissection of a squamous cell carcinoma in situ in the anal canal diagnosed by magnifying endoscopy with narrow-band imaging. |
| Q35850176 | Epidermoid cancer of the anal canal |
| Q37427844 | Epidermoid cancers of the anal canal: current treatment |
| Q37427561 | Epidermoid carcinoma of the anal canal |
| Q44546849 | Epidermoid carcinomas of the anal canal treated with definitive radiation therapy in a series of 305 patients |
| Q94602697 | Evaluating treatment protocols for rectal squamous cell carcinomas: the Duke experience and literature |
| Q36944546 | Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. |
| Q32149076 | Experience with split-course external beam irradiation +/- chemotherapy and integrated Ir-192 high-dose-rate brachytherapy in the treatment of primary carcinomas of the anal canal |
| Q35879804 | Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients |
| Q33776972 | FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma |
| Q33860524 | First Case of the Cervical Lymph Node as the Only Site of Metastasis from Anal Cancer |
| Q36009950 | French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients |
| Q36608530 | Gene expression reveals two distinct groups of anal carcinomas with clinical implications |
| Q36765574 | Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer |
| Q52723352 | Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT. |
| Q34640551 | HIV- positive anal cancer: an update for the clinician |
| Q90472694 | HYPHYCA: a prospective study in 613 patients conducting a comprehensive analysis for predictive factors of physiological 18F-FDG anal uptake |
| Q43594786 | High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study |
| Q33787728 | Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal |
| Q35927962 | IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center |
| Q64084335 | Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) |
| Q33578833 | Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data |
| Q36115829 | Impact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: Analysis of the National Cancer Data Base. |
| Q58806082 | Impact of intensity modulated radiation therapy on survival in anal cancer |
| Q47140514 | Impact of neoadjuvant and adjuvant radiotherapy on disease-specific survival in patients with stages II-IV rectal cancer |
| Q90574664 | Implementation of the Chick Chorioallantoic Membrane (CAM) Model in Radiation Biology and Experimental Radiation Oncology Research |
| Q39405366 | Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database |
| Q64973824 | In regard to Kapp et al.: experience with split-course external beam irradiation +/- chemotherapy and integrated (192)Ir high-dose-rate brachytherapy in the treatment of primary carcinomas of the anal canal. IJROBP 2001;49:997--1005. |
| Q74752442 | Induction chemotherapy and radiotherapy in loco-regionally advanced epidermoid carcinoma of the anal canal |
| Q36907276 | Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal |
| Q35530203 | Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities. |
| Q37258940 | Intensity-modulated radiation therapy for gastrointestinal tumors |
| Q83349480 | Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal |
| Q38783988 | Intensity-modulated radiotherapy for squamous cell carcinoma of the anal canal: efficacy of a low daily dose to clinically negative regions |
| Q34499551 | Interstitial high-dose rate brachytherapy as boost for anal canal cancer |
| Q64094440 | Local excision for patients with stage I anal canal squamous cell carcinoma can be curative |
| Q35039830 | Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy |
| Q53506070 | Locally advanced anal canal carcinoma: is the addition of cetuximab the answer? |
| Q39052267 | Locally advanced vulva cancer: A single centre review of anovulvectomy and a systematic review of surgical, chemotherapy and radiotherapy alternatives. Is an international collaborative RCT destined for the "too difficult to do" box? |
| Q39178776 | Long-standing Crohn's disease and its implication on anal squamous cell cancer management |
| Q35400610 | Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292). |
| Q36463914 | Long-term outcomes of chemoradiation for anal cancer patients |
| Q48923171 | Long-term quality of life after radiotherapy for the treatment of anal cancer. |
| Q64089195 | Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis |
| Q30415832 | Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin |
| Q48244052 | Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation |
| Q47734415 | Management of Stage I Squamous Cell Carcinoma of the Anal Canal |
| Q35527086 | Management of colorectal cancers. |
| Q35086388 | Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review. |
| Q47746190 | Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network |
| Q37251305 | Management of two cases of recurrent anal carcinoma |
| Q34276791 | Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm? |
| Q37340084 | Mitomycin and Fluorouracil With Concurrent Radiation (FUMIR) Regimen for Anal Cancer |
| Q43973278 | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial |
| Q92487531 | Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers |
| Q34182566 | Multimodality therapy in penile cancer: when and which treatments? |
| Q35579023 | Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy. |
| Q37174058 | Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection |
| Q34183257 | Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer |
| Q35117964 | Neoplasms of anal canal and perianal skin. |
| Q52632144 | Neutrophil-Based Drug Delivery Systems. |
| Q38405569 | Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study |
| Q38627519 | Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study |
| Q34996001 | Novel techniques in the delivery of radiation in pediatric oncology |
| Q33803090 | Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315 |
| Q33763918 | One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: analysis of outcomes and toxicity. |
| Q90173109 | Optimal Radiotherapy Dose in Anal Cancer: Trends in Prescription Dose and Association with Survival |
| Q36389393 | Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans |
| Q38227802 | Optimal treatment strategies for anal cancer |
| Q34259429 | Organ preservation for carcinoma of the larynx and hypopharynx |
| Q33788310 | Organ preservation. |
| Q97642102 | Organ preserving radiation strategies for penile cancer |
| Q90244191 | Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal |
| Q85203305 | Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva |
| Q47157384 | Overview of Recent Trends in the Management of Metastatic Anal Cancer |
| Q50260482 | PET imaging in anal canal cancer: a systematic review and meta-analysis |
| Q35073902 | Palliative and postoperative radiotherapy in biliary tract cancer |
| Q37153300 | Particle radiation therapy for gastrointestinal malignancies |
| Q92486858 | Patterns of care and outcomes of intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for anal cancer |
| Q26773698 | Pelvic radiotherapy and sexual function in women |
| Q38647761 | Pharmacotherapy of Anal Cancer |
| Q53236215 | Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal. |
| Q34246244 | Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer |
| Q52905730 | Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. |
| Q90416142 | Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC) |
| Q84090988 | Postoperative versus definitive chemoradiation in early-stage anal cancer. Results of a matched-pair analysis |
| Q56528378 | Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? |
| Q48101396 | Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapy |
| Q93090514 | Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT |
| Q38401237 | Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. |
| Q35850196 | Premalignant lesions of the anal canal and squamous cell carcinoma of the anal canal |
| Q64951252 | Primary tumor size as a prognosticator in anal cancer patients. |
| Q30416301 | Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11) |
| Q43453891 | Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). |
| Q37072485 | Prognostic factors for squamous cell cancer of the anal canal |
| Q57272683 | Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal |
| Q99630448 | Prognostic role of ultrasonography staging in patients with anal cancer |
| Q57617855 | Proliferation parameters in epidermoid carcinomas of the anal canal |
| Q33905348 | Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma |
| Q83468772 | Quality of life outcomes in patients with anal cancer after combined radiochemotherapy |
| Q43379654 | Quantitative FDG-PET/CT predicts local recurrence and survival for squamous cell carcinoma of the anus |
| Q34478729 | RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal |
| Q40683974 | Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome |
| Q34584811 | Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy |
| Q36877068 | Radical chemoradiotherapy for urethral squamous cell carcinoma: two case reports and a review of the literature |
| Q38233873 | Radio-chemotherapy in anal cancer: Institutional experience at a large radiation oncology center in Chile |
| Q35113390 | Radiochemotherapy in Anal Cancer: cCR, clinical outcomes and quality of life using two different treatment schedules |
| Q30840017 | Radionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer |
| Q24247566 | Radiotherapy versus combined modality therapy for anal carcinoma |
| Q39520534 | Radiotherapy with or without chemotherapy in the treatment of anal cancer: 20-year experience from a single institute |
| Q34584739 | Randomized clinical trials in rectal and anal cancer |
| Q98290253 | Rare Presentation of Cardiotoxicity Related to 5-Fluorouracil |
| Q56890232 | Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey |
| Q33797364 | Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology |
| Q44029160 | Rectal squamous cell carcinoma treated with chemoradiotherapy: report of six cases |
| Q38970764 | Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots? |
| Q37573426 | Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis |
| Q44520753 | Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal |
| Q77463859 | Role of a DT-diaphorase mutation in the response of anal canal carcinoma to radiation, 5-fluorouracil, and mitomycin C |
| Q43409549 | Role of brachytherapy in the treatment of cancers of the anal canal. Long-term follow-up and multivariate analysis of a large monocentric retrospective series. |
| Q92067229 | Role of pelvic chemoradiation therapy in patients with initially metastatic anal canal cancer: A National Cancer Database review |
| Q60629698 | Résection R0, seul facteur pronostique dans les amputations abdominopérinéales de rattrapage des cancers du canal anal (série consécutive de 95 patients) |
| Q84706668 | SEOM clinical guidelines for the treatment of anal cancer |
| Q33608156 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. |
| Q55278986 | Salvage Abdominoperineal Resection for Squamous Cell Anal Cancer: A 30-Year Single-Institution Experience. |
| Q42204118 | Saudi Oncology Society clinical management guideline series. Anal canal cancer 2014. |
| Q50442491 | Sentinel Node Biopsy in Squamous-Cell Carcinoma of the Anal Canal |
| Q38272464 | Shifting paradigm in the management of anal canal carcinoma |
| Q44264206 | Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and |
| Q82795933 | Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal? |
| Q57494898 | Single nucleotide polymorphism of GSTP1 and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy |
| Q58548056 | So Now My Patient Has Squamous Cell Cancer: Diagnosis, Staging, and Treatment of Squamous Cell Carcinoma of the Anal Canal and Anal Margin |
| Q47156788 | Social determinants of stage IV anal cancer and the impact of pelvic radiotherapy in the metastatic setting. |
| Q37005884 | Sphincter preservation in anal cancer: a brief review |
| Q37537210 | Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience |
| Q37353857 | Squamous cell cancer of the rectum |
| Q39436754 | Squamous cell carcinoma antigen: a potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin |
| Q32149105 | Squamous cell carcinoma of the anal canal |
| Q84526785 | Squamous cell carcinoma of the anal canal |
| Q34259455 | Squamous cell carcinoma of the anal canal and anal margin |
| Q35093611 | Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexuals |
| Q38712700 | Squamous-cell carcinoma of the anus: progress in radiotherapy treatment |
| Q52911705 | Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. |
| Q37525358 | Successful hepatectomy for metastatic squamous cell carcinoma of the anal canal-a case report |
| Q42118394 | Successful treatment of anal carcinoma with Paclitaxel, Cisplatin, and radiotherapy in a patient who developed a coronary syndrome from 5-fu. |
| Q40085443 | Surgery is essential in squamous cell cancer of the rectum. |
| Q38549935 | Surgical Options in the Treatment of Lower Gastrointestinal Tract Cancers |
| Q36496261 | Surgical salvage therapy of anal cancer |
| Q92486855 | Survival benefits and predictors of use of chemoradiation compared with radiation alone for early stage (T1-T2N0) anal squamous cell carcinoma |
| Q44990570 | Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study |
| Q52642515 | Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC). |
| Q88575201 | Systemic Therapies for Advanced Squamous Cell Anal Cancer |
| Q64071654 | Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy |
| Q33820797 | Technical aspects of radiation therapy for anal cancer |
| Q92610915 | Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014) |
| Q36788317 | The Human Papillomavirus Vaccine: Current Perspective and Future Role in Prevention and Treatment of Anal Intraepithelial Neoplasia and Anal Cancer |
| Q38929958 | The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. |
| Q35104586 | The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series |
| Q39233316 | The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. |
| Q28070412 | The Role of Lymphocytes in Radiotherapy-Induced Adverse Late Effects in the Lung |
| Q74510672 | The Swedish National Care Programme for Anal Carcinoma--implementation and overall results |
| Q89296351 | The case for nonsurgical therapy of nonmetastatic penile cancer |
| Q34501921 | The combined use of radiotherapy and chemotherapy in the treatment of solid tumours |
| Q35548994 | The differential diagnosis and interdisciplinary treatment of anal carcinoma |
| Q37123469 | The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer |
| Q43631944 | The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy |
| Q54975210 | The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy. |
| Q55250545 | The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. |
| Q42467862 | The role of MRI in the assessment of the local status of anal carcinomas and in their management |
| Q34957320 | The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal |
| Q44810868 | The treatment of squamous anal carcinoma: guidelines of the Italian Society of Colo-Rectal Surgery |
| Q34501956 | The use of chemoradiotherapy in oesophageal cancer |
| Q98164592 | Treatment algorithm and prognostic factors for patients with stage I-III carcinoma of the anal canal: a 20-year multicenter study |
| Q59621990 | Treatment of HIV-associated invasive anal cancer with combined chemoradiation |
| Q45269518 | Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients |
| Q44948367 | Treatment of anal carcinoma in immune-compromised patients |
| Q77916714 | Treatment of anal carcinoma in the elderly: feasibility and outcome of radical radiotherapy with or without concomitant chemotherapy |
| Q78094272 | Treatment of squamous cell anal canal carcinoma with pulsed dose rate brachytherapy. Feasibility study of a French cooperative group |
| Q97542012 | Treatment outcome after radiochemotherapy in anal cancer patients staged with 18F-FDG-PET-CT |
| Q55280333 | Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy. |
| Q84579627 | Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy |
| Q37861572 | Update on treatment advances in combined-modality therapy for anal and rectal carcinomas |
| Q36671886 | Value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: an update of the series and a review of the literature. |
| Q53331457 | Verrucous carcinoma (Buschke-Lowenstein) arising in a sacrococcygeal pilonidal sinus tract: report of a case. |
| Q38998542 | Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma: Effects on treatment-related side effects and survival |
| Q82970082 | [Anal HPV infections] |
| Q53285663 | [Anal cancer: diagnostic and differential diagnostic issues]. |
| Q82728703 | [Anal cancer] |
| Q77565530 | [Anorectal neuroendocrine carcinoma and small cell carcinoma. Report of two cases] |
| Q50555772 | [Cause-specific colostomy rates after radiotherapy for anal cancer: a Danish multicentre cohort study]. |
| Q77919363 | [Chemoradiotherapy in treatment of cancer of the anal canal] |
| Q74259005 | [Concomitant radiochemotherapy is superior to radiotherapy alone in the treatment of anal cancer: results of a randomized phase iii study] |
| Q87423478 | [Concurrent radiochemotherapy for the treatment of solid tumors] |
| Q73343064 | [Conservative treatment of anal canal carcinoma with external radiotherapy and interstitial brachytherapy, with or without chemotherapy: long-term results] |
| Q80567573 | [Diagnosis and therapy for anal carcinoma] |
| Q88104725 | [How long should we wait upon completion of chemoradiotherapy before assessment of tumor response in anal cancer?] |
| Q79907834 | [Initial pretherapeutic assessment of anal epidermoid carcinoma] |
| Q73267113 | [Radiochemotherapy in anal canal epidermoid cancer] |
Search more.